--- title: "Adagene (ADAG) news: offering" url: "https://aibio.space/companies/adagene/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ADAG offering news: Adagene prices US$70.0 million offering of 18,666,000 ADSs at US$3.75. Adagene Inc. (NASDAQ: ADAG), China." --- ADAG Adagene Inc. NASDAQ · China # Adagene (ADAG) news ADAG offering news Financings · 2026-04-02 ## [Adagene prices US$70.0 million offering of 18,666,000 ADSs at US$3.75](https://aibio.space/news/adagene-prices-us-70-0-million-offering-18-666-000-adss-us-3-75/) Adagene Inc. priced 18,666,000 American depositary shares at $3.75 for about $70.0 million gross, below the $4.61 last sale price on April 1. Leerink Partners LLC and LifeSci Capital LLC are joint book-running managers, and cash stood at $74.5 million at the end of 2025. ## Latest Adagene news 1. 2025-05-30 Financings [Adagene files to sell up to US$100,000,000 of ADSs at market](https://aibio.space/news/adagene-files-sell-up-us-100-000-000-adss-market/) Adagene Inc. filed a prospectus supplement for an at-the-market program of up to US$100 million of American depositary shares, sold through Leerink Partners. The filing repeats the warning that its auditor is in mainland China, where trading in its ADSs could be barred. ## Adagene at a glance - **Ticker**: ADAG - **Listing**: NASDAQ - **Country**: China - **Cash, Dec 31, 2025**: $74.5 million ### Related companies - [Joincare Pharmaceutical Group Industry Co.](https://aibio.space/companies/joincare-pharmaceutical-industry/) SSE: 600380 - [Hubei Guangji Pharmaceutical Co.](https://aibio.space/companies/hubei-guangji-pharmaceutical/) SZSE: 000952 - [Beijing Biostar Pharmaceuticals Co.](https://aibio.space/companies/beijing-biostar-pharmaceuticals/) HKEX: 2563 - [Zhejiang Xianju Pharmaceutical Co.](https://aibio.space/companies/zhejiang-xianju-pharmaceutical/) SZSE: 002332 - [Shaanxi Kanghui Pharmaceutical Co.](https://aibio.space/companies/shaanxi-kanghui-pharmaceutical/) SSE: 603139 - [Shanghai Fosun Pharmaceutical (Group) Co.](https://aibio.space/companies/shanghai-fosun-pharmaceutical/) SSE: 600196 - [Jiangxi Synergy Pharmaceutical Co.](https://aibio.space/companies/jiangxi-synergy-pharmaceutical/) SZSE: 300636 - [Shanghai Shenqi Pharmaceutical Investment Management Co.](https://aibio.space/companies/shanghai-shenqi-pharmaceutical-investment-management/) SSE: 600613 ### Also on NASDAQ - [Tyra Biosciences](https://aibio.space/companies/tyra-biosciences/) TYRA - [Kiora Pharmaceuticals](https://aibio.space/companies/kiora-pharmaceuticals/) KPRX - [Estrella Immunopharma](https://aibio.space/companies/estrella-immunopharma/) ESLA - [Tectonic Therapeutic](https://aibio.space/companies/tectonic-therapeutic/) TECX - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) AMRX - [Replimune Group](https://aibio.space/companies/replimune/) REPL ## Adagene annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$7.7 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | [$103,204](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | | Research and development | [$22.0 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | [$28.8 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | | Net income (loss) | [-$17.6 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | [-$33.4 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | | Cash from operations | [-$15.7 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | [-$29.7 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | | Cash and equivalents | [$74.5 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | [$85.2 million](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | [$0](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038612/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $74.5 million, plus short-term investments of $0, $74.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Adagene Has Adagene raised money recently? Our latest story on this, dated Apr 2, 2026: "Adagene prices US$70.0 million offering of 18,666,000 ADSs at US$3.75". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/adagene-prices-us-70-0-million-offering-18-666-000-adss-us-3-75/). What is the ticker symbol of Adagene? Adagene Inc. trades under the ticker ADAG on NASDAQ. Where is Adagene listed? Adagene Inc. is listed on NASDAQ. What is the SEC CIK of Adagene? The SEC Central Index Key (CIK) for Adagene Inc. is 1818838. Its filings are on SEC EDGAR. How many shares does Adagene have outstanding? 59,231,993 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-01. Which country or territory is Adagene listed under? Our directory records Adagene Inc. under China. What does Adagene do? Our directory classifies Adagene Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Adagene? The ISIN recorded for Adagene Inc. is US0053291078. Does aibio.space cover Adagene? aibio.space lists Adagene Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Adagene incorporated? SEC records list its state or country of incorporation as E9. What was Adagene's revenue last year? $7.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Adagene profitable? Adagene Inc. reported a net loss of $17.6 million for the fiscal year ended Dec 31, 2025, and used $15.7 million of cash in operations, per its annual report to the SEC. How much does Adagene spend on research and development? $22.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Adagene have? $74.5 million in cash and short-term investments at Dec 31, 2025, per its 20-F. What is the latest Adagene (ADAG) stock news? Our latest story on Adagene, dated Apr 2, 2026: "Adagene prices US$70.0 million offering of 18,666,000 ADSs at US$3.75". Adagene Inc. priced 18,666,000 American depositary shares at $3.75 for about $70.0 million gross, below the $4.61 last sale price on April 1. Leerink Partners LLC and LifeSci Capital LLC are joint book-running managers, and cash stood at $74.5 million at the end of 2025. [Source](https://aibio.space/news/adagene-prices-us-70-0-million-offering-18-666-000-adss-us-3-75/). ## Investor discussion: Adagene Members talk about Adagene (ADAG). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Adagene, newest first. Each line links the filing it comes from. 1. 2026-04-02 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1818838/000110465926038861/tm2610656-1_424b5.htm) 2. 2025-07-01 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1818838/000110465925064443/tm2518776d1_ex99-1.htm) 3. 2025-05-30 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1818838/000110465925054974/tm2511065-6_424b5.htm) 4. 2025-05-09 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1818838/000110465925046772/tm2511065-1_f3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ADAG on TradingView](https://www.tradingview.com/symbols/NASDAQ-ADAG/). ## SEC filings and registration - **SEC name**: Adagene Inc. - **CIK**: 1818838 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ADAG (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer
Emerging growth company - **Business address**: 4F, BUILDING C14, NO. 218, XINGHU STREET, JIANGSU, China, 00000 - **Phone**: 86-512-87773632 - **Shares outstanding**: 59,231,993 as of 2025-12-31 (20-F filed 2026-04-01) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1818838/000110465926110982/tm2625847d1_6k.htm) filed 2026-09-25 - [6-K](https://www.sec.gov/Archives/edgar/data/1818838/000110465926109485/tm2625845d1_6k.htm) filed 2026-09-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1818838/000110465926106554/tm2624950d1_6k.htm) filed 2026-09-10 - [6-K](https://www.sec.gov/Archives/edgar/data/1818838/000110465926106137/tm2624926d1_6k.htm) filed 2026-09-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1818838/000110465926094468/adag-20260812x6k.htm) filed 2026-08-12 - [6-K](https://www.sec.gov/Archives/edgar/data/1818838/000110465926080580/tm2619738d1_6k.htm) filed 2026-07-06 - [6-K](https://www.sec.gov/Archives/edgar/data/1818838/000110465926044885/tm2611979d1_6k.htm) filed 2026-04-17 - [424B5](https://www.sec.gov/Archives/edgar/data/1818838/000110465926039189/tm2610656-2_424b5.htm) filed 2026-04-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001818838), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Adagene Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ADAG, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Adagene Inc. - **Ticker**: ADAG - **Listing**: NASDAQ - **Country or territory**: China - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0053291078 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ADAG/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/adagene/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Adagene (ADAG) news: offering", 2026-10-31, https://aibio.space/companies/adagene/